of leukotrienes. Among such antileukotriene drugs, specific receptor antagonists of the Background -Leukotriene receptor antagonists significantly blunt allergen-in-cysteinyl leukotrienes (LTC 4 , LTD 4 and LTE 4 ) have been found to inhibit asthmatic reacduced bronchoconstriction in asthmatic subjects. Inhibitors of leukotriene syn-tions induced by allergens, 3-6 exercise, 7-9 and aspirin. 13 which has a pivotal role in the stimulation-evoked synthesis of leukotrienes asthma and bronchial hyperresponsiveness to histamine were recruited. On two from arachidonic acid. Consistent with this mode of action, BAYx 1005 has been found to different occasions each subject inhaled a single dose of allergen, previously de-inhibit IgE-dependent leukotriene formation in human lung in vitro, as well as the allergentermined to cause at least a 20% fall in forced expiratory volume in one second induced reactions in isolated human bronchi and animal models of asthma.
used during the study days. Short acting his- nebuliser generated an aerosol with a mass 1 Dose used during the blinded sessions (see methods)
median particle aerodynamic diameter of 2 Geometric mean.
4.1 m and the output was set to 7.1 l per breath. Pulmonary function was measured as FEV 1 on a spirometer (Vitalograph MDI Comthe allergens used for provocation. Criteria for pact, Fö rbandsmaterial, Sweden). Three coninclusion in the study included forced ex-centrations of allergen extract (1000, 10 000, piratory volume in one second (FEV 1 ) of >75% and 100 000 SQ/ml; SQ=standardised quality, predicted and bronchial hyperresponsiveness the manufacturer's unit for allergen strength) to histamine, defined as a provocative dose were prepared by dissolving lyophilised powder causing a 20% fall in FEV 1 (PD 20 ) of <1210 g in diluent. The extracts (Aquagen) and the measured as previously described. 27 The study diluent were from ALK Laboratories, Copenwas approved by the local ethics committee hagen, Denmark. By using the three conand the Swedish Medical Products Agency centrations and by varying the number of (Läkemedelsverket). The patients gave in-breaths from the nebuliser, the protocol used formed consent.
during the screening provocation resulted in approximately half log increments in the cumulated dose of allergen.
 
Baseline FEV 1 was defined as the best of All patients first underwent a screening allergen three recordings made five minutes apart. test to establish their current sensitivity to aller-Spirometric values were obtained at hourly gen. The PD 20 was determined by linear intervals after drug administration and the interpolation from the relation between FEV 1 value four hours after the drug was used cumulated dose of inhaled allergen and per-as the baseline value for the ensuing allergen challenge. All challenges were preceded by centage change in FEV 1 . Within six months inhalation of the diluent and, provided FEV 1 of the screening challenge (mean interval 120 did not change by more than 10%, bronchodays, range 32-180) the double blind, placebo provocation with allergen was started. Pulcontrolled, crossover drug trial was started. On monary function was measured every 15 mintwo separate days the patients received either utes after inhalation of allergen until the FEV 1 750 mg BAYx 1005 or placebo four hours behad returned to within 10% of baseline, and fore allergen challenge. Patients reported fastthereafter hourly for up to six hours. For moniing to the clinic at the same time of the day toring of late asthmatic reactions the patients (07.30 hours) and ingested the tablets under measured their peak expiratory flow rate supervision at about 08.00 hours.
(PEFR) with a mini-Wright flow meter hourly Breakfast was given two hours later. The after discharge from the hospital and until redose of BAYx 1005 used was the highest that tiring to bed. The occurrence of a late airway had been cleared for human studies at the time reaction (LAR) was defined as a 20% drop in the study was performed. The time for pre-PEFR 3-12 hours after the early asthmatic administration was selected from data on peak reaction (EAR). The patients returned to the plasma concentration (3-5 hours) and plasma clinic the morning after each treatment day for half life (3-5 hours) previously determined in physical examination, spirometric tests, and pharmacokinetic studies of the compound in sampling of blood. man (data on file, Bayer AG, Germany). The compound BAYx 1005 12 was supplied by Bayer AG, Leverkusen, Germany, as 250 mg of a     4 crystalline powder in coated tablets. The two Urine was collected at one hour intervals blinded bronchoprovocations were separated before drug or placebo, four hours after drug by an interval of about four weeks (mean 27 administration, and for up to six hours after days; range 20-56) and performed by inhala-the challenge. The samples were divided tion of the same single dose of allergen on into different aliquots and stored separately both occasions. The dose used in the blinded at −20°C and −70°C. The concentration provocations ( 26.5 (2.0)% and 23.5 (3.3)% for screening and the clinic, transported on dry ice, and stored at below −15°C until analysis was performed placebo, respectively. For two subjects (4 and 10), the allergen dose selected for use in the at the human pharmacokinetic department of Bayer AG in Leverkusen, Germany. The double blind sessions (see methods) differed from the dose of allergen inhaled at screening. HPLC method had a detection limit of 8 g/l, a precision which varied from 7.6% to 12.7%, Subject 1 had late asthmatic reactions on screening and following placebo, but not after and an accuracy which deviated by a maximum of 3.8%.
BAYx 1005. The airway response to allergen was substantially inhibited when BAYx 1005 was given prior to challenge, both with respect to the    Geometric mean PD 20 values were calculated amplitude of the fall in FEV 1 and the duration of the reaction (fig 1) . Figure 2 shows the peak on log transformed raw data. The area under the curves (AUC) for FEV 1 versus time and fall for each individual and the group means during the two sessions. The fall in FEV 1 was urinary LTE 4 versus time were calculated using the trapezoidal rule for integration. Results are smaller after BAYx 1005 for all subjects. The mean peak fall after placebo was 21.0 (3.0)% presented as means (SE) and mean differences between treatments with 95% confidence in-compared with 7.1 (1.7)% after BAYx 1005.
The mean difference between treatments was tervals (CI). The data for pulmonary function and urinary levels of LTE 4 were found to be 13.9 (95% CI 7.0 to 20.8; p<0.001). Thus, the mean inhibition of the fall in FEV 1 by normally distributed (SigmaStat software for IBM PC, Jandel Scientific, USA). The Stu-BAYx 1005 was 70.0 (7.0)%. The results were unrelated to the order in which treatments were dent's paired t test was used to compare group means.
given. The mean area under the FEV 1 -time curve Differences were considered to be significant when the p value was <0.05. Period and carry-(AUC FEV 1 ) during the first hour after challenge was 5.3 (0.7) and 1.5 (0.4) for placebo over effects of the drug treatments were analysed by the method of Hills and Armitage. 29 and BAYx 1005, respectively. The mean difference between treatments was 3.8 (95% CI 2.2 to 5.4), p<0.001, which corresponds to a mean inhibition of the immediate airway Results Baseline pulmonary function was not sig-response of 74 (10)%. The inhibition of the response during the first two hours after chalnificantly different on the two study days (fig  1) , nor was there any significant change in lenge was similarly calculated to be 63 (10.9)%.
Group mean baseline values for the urinary FEV 1 during the four hours following drug administration (fig 1) . There were no subjective excretion of LTE 4 did not differ on the two study days (19.5 (6.7) and 23.5 (5.6) ng/mmol or objective signs of drug related side effects after intake of 750 mg BAYx 1005.
creatinine for placebo and drug, respectively), neither were there significant changes in the There was good agreement between the fall in FEV 1 at screening and placebo for the eight levels of urinary LTE 4 in the time between drug intake and allergen challenge. Thus, at the time subjects who inhaled the same dose of allergen on both occasions with a mean maximal fall of of challenge urinary LTE 4 levels were 21.5 (4.7)
group.bmj.com on April 20, 2017 -Published by http://thorax.bmj.com/ Downloaded from bronchoconstriction. Our findings with BAYx 1005 thus confirm previous indications 25 26 that inhibitors of leukotriene biosynthesis attenuate allergen-induced bronchoconstriction. The inhibition of the early response in this study with BAYx 1005 was superior to that reported for the more short lived leukotriene biosynthesis inhibitor MK-886, 25 and was identical to that observed with another potent and long lived FLAP antagonist, MK-591. 26 The leukotriene biosynthesis inhibitors so far reported to protect against allergen-induced bronchoconstriction (MK-886, 25 MK-591, 26 and BAYx 1005) are all FLAP antagonists, whereas the drugs that have failed in allergen challenges of asthmatic subjects 23 24 are directly acting 5-lipoxygenase inhibitors. Studies are required to establish if there is a real difference between the effects with potent receptor antagonists of cysteinyl leukotrienes. 3 4 Likewise, in a parallel study of the effect of BAYx 1005 on allergen-induced and 27.6 (4.7) ng/mmol creatinine following placebo and BAYx 1005, respectively. bronchoconstriction 30 a lower dose of BAYx 1005 (500 mg) was given for 3.5 days and The net urinary excretion of LTE 4 (value after challenge -prechallenge value) was in-caused about 60% inhibition of the maximal fall in FEV 1 during the early response. The creased after placebo (fig 3) . This increase was significantly inhibited during the session when similar effects of several structurally unrelated drugs that inhibit the action or formation of BAYx 1005 had been given. Thus, the mean AUC 0-2 hours after challenge for the net leukotrienes by different mechanisms therefore reinforces the suggestion that leukotrienes are increase in urinary LTE 4 was 1.7 (0.9) for the placebo session and 0.4 (0.6) for the drug major mediators of the early asthmatic response in humans. Secondly, the similar effects of treatment session (p<0.05), corresponding to an inhibition of 76%. The mean difference leukotriene biosynthesis inhibitors and receptor antagonists of cysteinyl leukotrienes on the between treatments was 1.3 (95% CI −0.1 to 2.7). There were no differences in AUC for early response to allergen suggests that it is the bronchoconstrictive cysteinyl leukotrienes urinary LTE 4 between drug and placebo at time points later than three hours after challenge. rather than the leucocyte attractant LTB 4 that mediate this particular response. Despite the similar degree of inhibition of urinary LTE 4 excretion and bronchoconstriction in One of the main end points in this study was to measure LTE 4 in urine collected before, the group, there was no correlation between the two responses in individuals (r=0.20 for during, and after provocation in order to follow the degree of in vivo inhibition produced by AUC LTE 4 at 0-2 hours versus AUC FEV 1 at 0-1 hours; p>0.58).
BAYx 1005. As expected, 19-22 the levels of LTE 4 were increased in the samples of urine collected Measurements of drug plasma concentrations confirmed the coding, with no de-within two hours after the placebo treated challenge with allergen. This increase was subtectable BAYx 1005 (<8 g/l) after placebo. On drug treatment days the peak concentration of stantially inhibited by BAYx 1005. The magnitude of inhibition of net release (level BAYx 1005 was 10.5 mg/l (about 30 M) (range 5.3-19.8 mg/l; SE 2.3) and occurred at after challenge -level before challenge) of LTE 4 (76%) was similar to the inhibition of the 3.5 (0.4) hours. The mean plasma half life of the drug was found to be 5.2 (1.5) hours. There bronchoconstrictor response by the drug (70-74%, depending upon whether the peak fall in was no correlation between the drug levels in the subjects and the degree of inhibition of FEV 1 or AUC at 0-1 hours was measured).
There is therefore good reason to believe that either the airway response or the urinary excretion of LTE 4 (r<0.5 for all tested hypo-the inhibition by BAYx 1005 of the increase in urinary levels of LTE 4 seen after challenge theses).
reflected its ability to inhibit pulmonary formation of leukotrienes and consequently the allergen-induced airway obstruction. There Discussion The leukotriene biosynthesis inhibitor BAYx was, however, no relation between the drug plasma concentration and the degree of in-1005 significantly inhibited allergen-induced with drug effects on responses caused by the local release of leukotrienes in the airways. 5 6 25 26 In contrast to the inhibition of the allergen- 
